BRISBANE, Calif.--(BUSINESS WIRE)--
Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W.
Aguiar, Innoviva's President and Chief Executive Officer and Eric
d'Esparbes, SVP and Chief Financial Officer will present at the Cantor
Fitzgerald Global Healthcare Conference on Tuesday, September 26 at 4:35
EDT, at the InterContinental New York Barclay Hotel in New York City.
The presentation will be webcast live and archived for 90 days. Please
follow the link below or visit the IR section of the Innoviva website to
view the presentation: http://wsw.com/webcast/cantor6/inva
Innoviva is focused on bringing compelling new medicines to patients in
areas of unmet need by leveraging its significant expertise in the
development, commercialization and financial management of
bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory
assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO®
ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva
and GSK. Under the agreement with GSK, Innoviva is eligible to receive
associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO®
ELLIPTA®. In addition, Innoviva retains a 15 percent economic interest
in future payments made by GSK for earlier-stage programs partnered with
Theravance BioPharma, Inc., including the closed triple combination
therapy for Chronic Obstructive Pulmonary Disease (COPD). For more
information, please visit Innoviva's website at www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the
GlaxoSmithKline group of companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170921006143/en/
Senior Vice President and Chief
Source: Innoviva, Inc.
News Provided by Acquire Media